Intellia Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. 

CEO
John M. Leonard
CEOJohn M. Leonard
Employees
403
Employees403
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
403
Employees403

NTLA Key Statistics

Market cap
2.02B
Market cap2.02B
Price-Earnings ratio
-3.68
Price-Earnings ratio-3.68
Dividend yield
Dividend yield
Average volume
8.39M
Average volume8.39M
High today
$19.41
High today$19.41
Low today
$17.27
Low today$17.27
Open price
$17.38
Open price$17.38
Volume
6.54M
Volume6.54M
52 Week high
$21.47
52 Week high$21.47
52 Week low
$5.90
52 Week low$5.90

NTLA News

TipRanks 20h
Cathie Wood’s ARK Investment buys 99K shares of Intellia Therapeutics today

20:32 EDT Cathie Wood’s ARK Investment buys 99K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for real-time, mar...

TipRanks 2d
Cathie Wood Boosts Stakes in Intellia and L3Harris, Cuts Kratos Holdings

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio adjustments on Monday, September 29, according to daily fund disclosures. The ace h...

TipRanks 3d
Cathie Wood Snaps Up Kodiak AI and Intellia Stocks, Offloads Roblox and Kratos Shares

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Friday, September 26, according to daily fund disclosures. T...

Analyst ratings

77%

of 26 ratings
Buy
76.9%
Hold
19.2%
Sell
3.8%

More NTLA News

TipRanks 6d
Buy Rating for Intellia Therapeutics: Promising Long-Term Data and Market Potential for nex-z in ATTR-PN Treatment

Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Intellia Therapeutics, retaining the price target of $25.00. Elevate Your Investing Stra...

TipRanks 6d
Intellia Therapeutics Announces Positive Phase 1 Trial Results

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

Benzinga 6d
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran...

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
TipRanks 6d
Intellia Therapeutics announces longer-term Phase 1 data for nex-z

Intellia Therapeutics (NTLA) announced longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran for the treatment of he...

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.